Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 17102050 | METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTION | November 2020 | March 2021 | Allow | 4 | 0 | 0 | Yes | No |
| 17102059 | METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTION | November 2020 | April 2021 | Allow | 4 | 0 | 0 | No | No |
| 17084014 | METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTION | October 2020 | September 2021 | Allow | 11 | 1 | 0 | No | No |
| 17084023 | METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTION | October 2020 | March 2021 | Allow | 5 | 0 | 0 | No | No |
| 17079070 | METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTION | October 2020 | November 2021 | Allow | 13 | 2 | 0 | No | No |
| 16935007 | METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTION | July 2020 | November 2020 | Allow | 4 | 0 | 0 | No | No |
| 16935011 | METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTION | July 2020 | February 2021 | Allow | 7 | 0 | 0 | No | No |
| 16932294 | OPTIMIZED PROTEIN LINKERS AND METHODS OF USE | July 2020 | May 2021 | Allow | 9 | 1 | 1 | No | No |
| 16915087 | METHODS FOR DECONTAMINATING CIRCUITS FOR PRODUCING GLUCOSE POLYMERS AND HYDROLYSATES OF GLUCOSE POLYMERS | June 2020 | September 2023 | Abandon | 38 | 1 | 0 | No | No |
| 16914203 | MODIFIED CASCADE RIBONUCLEOPROTEINS AND USES THEREOF | June 2020 | February 2021 | Allow | 7 | 0 | 1 | Yes | No |
| 16898161 | METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTION | June 2020 | November 2021 | Abandon | 17 | 2 | 0 | Yes | No |
| 16898186 | METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTION | June 2020 | August 2023 | Abandon | 38 | 0 | 1 | No | No |
| 16898197 | METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTION | June 2020 | August 2023 | Abandon | 38 | 0 | 1 | No | No |
| 16896731 | TYPE V CRISPR/CAS EFFECTOR PROTEINS FOR CLEAVING SSDNAS AND DETECTING TARGET DNAS | June 2020 | June 2021 | Allow | 12 | 1 | 1 | No | No |
| 16892631 | METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTION | June 2020 | July 2020 | Allow | 2 | 0 | 0 | Yes | No |
| 16892663 | METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTION | June 2020 | July 2020 | Allow | 2 | 0 | 0 | No | No |
| 16864220 | METHODS AND USE OF INDUCING APOPTOSIS IN CANCER CELLS | May 2020 | October 2024 | Abandon | 54 | 1 | 0 | No | No |
| 16844059 | MODIFIED BINDING PROTEINS INHIBITING THE VEGF-A RECEPTOR INTERACTION | April 2020 | November 2024 | Abandon | 56 | 1 | 0 | No | No |
| 16825807 | METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTION | March 2020 | August 2023 | Abandon | 41 | 0 | 1 | No | No |
| 16643402 | METHOD FOR MODIFYING TARGET SITE IN DOUBLE-STRANDED DNA IN CELL | February 2020 | January 2021 | Allow | 11 | 1 | 1 | No | No |
| 16790368 | METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTION | February 2020 | June 2020 | Allow | 4 | 0 | 0 | No | No |
| 16789049 | CASZ COMPOSITIONS AND METHODS OF USE | February 2020 | September 2021 | Allow | 19 | 2 | 0 | Yes | No |
| 16781888 | ALGORITHMS FOR DISEASE DIAGNOSTICS | February 2020 | November 2024 | Abandon | 57 | 0 | 1 | No | No |
| 16659277 | SINGLE NUCLEOTIDE POLYMORPHISMS (SNP) AND ASSOCIATION WITH RESISTANCE TO IMMUNE TOLERANCE INDUCTION | October 2019 | August 2023 | Abandon | 46 | 0 | 1 | No | No |
| 16577740 | METHODS AND COMPOSITIONS FOR DETECTING A TARGET RNA | September 2019 | May 2022 | Allow | 32 | 3 | 0 | Yes | No |
| 16577696 | METHODS AND COMPOSITIONS FOR DETECTING A TARGET RNA | September 2019 | May 2022 | Allow | 32 | 3 | 0 | Yes | No |
| 16560711 | METHODS AND COMPOSITIONS FOR CLASSIFICATION OF SAMPLES | September 2019 | November 2024 | Abandon | 60 | 0 | 1 | No | No |
| 16554225 | MODIFIED CASCADE RIBONUCLEOPROTEINS AND USES THEREOF | August 2019 | May 2020 | Allow | 9 | 0 | 0 | Yes | No |
| 16455342 | GENOMIC PROBES | June 2019 | September 2021 | Allow | 26 | 4 | 0 | Yes | No |
| 16461992 | COMPOUNDS WITH ANTI-TUMOR ACTIVITY AGAINST CANCER CELLS BEARING EGFR OR HER2 EXON 20 MUTATIONS | May 2019 | May 2022 | Allow | 36 | 1 | 1 | Yes | No |
| 16343364 | SYSTEMS AND METHODS FOR DETECTING DISSEMINATED OR CIRCULATING CELLS OR DNA | April 2019 | July 2022 | Abandon | 39 | 1 | 1 | No | No |
| 16385383 | METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTION | April 2019 | February 2023 | Allow | 46 | 0 | 0 | No | No |
| 16383433 | METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTION | April 2019 | March 2020 | Allow | 11 | 0 | 0 | Yes | No |
| 16383412 | METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTION | April 2019 | February 2020 | Allow | 10 | 0 | 0 | No | No |
| 16383443 | METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTION | April 2019 | January 2020 | Allow | 9 | 0 | 0 | No | No |
| 16383422 | METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTION | April 2019 | January 2020 | Allow | 9 | 0 | 0 | No | No |
| 16382100 | METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTION | April 2019 | December 2019 | Allow | 8 | 0 | 0 | No | No |
| 16382096 | METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTION | April 2019 | November 2019 | Allow | 7 | 0 | 0 | No | No |
| 16382097 | METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTION | April 2019 | December 2019 | Allow | 8 | 0 | 0 | No | No |
| 16382093 | METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTION | April 2019 | October 2019 | Allow | 6 | 0 | 0 | No | No |
| 16380758 | METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTION | April 2019 | October 2019 | Allow | 7 | 0 | 0 | No | No |
| 16380781 | METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTION | April 2019 | October 2019 | Allow | 7 | 0 | 0 | No | No |
| 16278438 | OVEREXPRESSION OF FOXC1 TO TREAT CORNEAL VASCULARIZATION | February 2019 | January 2021 | Allow | 23 | 2 | 0 | No | No |
| 16277090 | METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTION | February 2019 | September 2019 | Allow | 7 | 0 | 0 | No | No |
| 16276348 | METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTION | February 2019 | August 2019 | Allow | 6 | 0 | 0 | Yes | No |
| 16276352 | METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTION | February 2019 | March 2020 | Allow | 13 | 1 | 0 | No | No |
| 16276356 | METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTION | February 2019 | August 2019 | Allow | 6 | 0 | 0 | No | No |
| 16276343 | METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTION | February 2019 | June 2019 | Allow | 4 | 0 | 0 | Yes | No |
| 16274770 | SYNTHETIC TRANSCRIPTIONAL REGULATOR COMPOSITIONS AND METHODS | February 2019 | March 2022 | Abandon | 37 | 3 | 0 | No | No |
| 16262257 | TYPE V CRISPR/CAS EFFECTOR PROTEINS FOR CLEAVING SSDNAS AND DETECTING TARGET DNAS | January 2019 | August 2023 | Abandon | 54 | 1 | 0 | No | No |
| 16201855 | METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTION | November 2018 | May 2019 | Allow | 6 | 0 | 0 | Yes | No |
| 16201862 | METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTION | November 2018 | February 2020 | Allow | 14 | 1 | 0 | Yes | No |
| 16201853 | METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTION | November 2018 | May 2019 | Allow | 6 | 0 | 0 | Yes | No |
| 16201865 | METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTION | November 2018 | February 2020 | Allow | 14 | 1 | 0 | Yes | No |
| 16201836 | METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTION | November 2018 | May 2019 | Allow | 6 | 1 | 0 | Yes | No |
| 16201848 | METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTION | November 2018 | April 2019 | Allow | 5 | 0 | 0 | No | No |
| 16189683 | Combinatorial Metabolic Engineering Using a CRISPR System | November 2018 | September 2023 | Abandon | 58 | 2 | 1 | No | No |
| 16181679 | DIAGNOSTIC SEQUENCING VIA TABLETS | November 2018 | July 2022 | Abandon | 44 | 2 | 1 | No | No |
| 16124252 | MYCOBACTERIOPHAGES CAPABLE OF DELIVERING AUTO-LUMINESCENT ELEMENTS AND USES THEREOF | September 2018 | April 2021 | Allow | 31 | 2 | 0 | Yes | No |
| 16105502 | Fusion Polymerase and Method for Using the Same | August 2018 | December 2022 | Allow | 52 | 1 | 0 | No | No |
| 16054513 | RNA-GUIDED NUCLEIC ACID MODIFYING ENZYMES AND METHODS OF USE THEREOF | August 2018 | August 2019 | Allow | 13 | 2 | 1 | No | No |
| 16033832 | TRANSFORMANT, AND METHOD FOR PRODUCING TRANSFERRIN | July 2018 | July 2019 | Allow | 12 | 1 | 0 | Yes | No |
| 16033016 | METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTION | July 2018 | March 2019 | Allow | 8 | 1 | 0 | No | No |
| 16033002 | METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTION | July 2018 | July 2019 | Allow | 12 | 1 | 1 | Yes | No |
| 16033005 | METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTION | July 2018 | July 2019 | Allow | 12 | 1 | 1 | Yes | No |
| 16021700 | MATERIALS AND METHODS FOR DETERMINING CANCER RISK | June 2018 | September 2021 | Allow | 39 | 0 | 0 | Yes | No |
| 16007541 | RARE NUCLEIC ACID DETECTION | June 2018 | May 2023 | Abandon | 59 | 4 | 0 | No | No |
| 16007498 | PLASMA/SERUM TARGET ENRICHMENT | June 2018 | May 2022 | Abandon | 47 | 3 | 0 | No | No |
| 16007427 | NEGATIVE-POSITIVE ENRICHMENT FOR NUCLEIC ACID DETECTION | June 2018 | January 2023 | Abandon | 55 | 4 | 0 | No | No |
| 16007510 | SELECTIVE PROTECTION OF NUCLEIC ACIDS | June 2018 | May 2023 | Abandon | 59 | 4 | 0 | No | No |
| 16060759 | METHODS AND COMPOSITIONS FOR ENHANCED NUCLEASE-MEDIATED GENOME MODIFICATION AND REDUCED OFF-TARGET SITE EFFECTS | June 2018 | April 2022 | Abandon | 46 | 3 | 0 | No | No |
| 16002602 | Methods and Compositions for Modifying a Single Stranded Target Nucleic Acid | June 2018 | July 2019 | Allow | 14 | 1 | 0 | Yes | No |
| 15965921 | COMPOSITIONS AND METHODS OF ENGINEERED CRISPR-CAS9 SYSTEMS USING SPLIT-NEXUS CAS9-ASSOCIATED POLYNUCLEOTIDES | April 2018 | July 2021 | Allow | 39 | 0 | 0 | Yes | No |
| 15965598 | METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTION | April 2018 | March 2022 | Abandon | 46 | 0 | 1 | Yes | No |
| 15965603 | METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTION | April 2018 | March 2022 | Abandon | 46 | 0 | 1 | No | No |
| 15959782 | METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTION | April 2018 | March 2022 | Abandon | 47 | 0 | 1 | Yes | No |
| 15959762 | METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTION | April 2018 | February 2022 | Abandon | 46 | 0 | 1 | No | No |
| 15959802 | METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTION | April 2018 | March 2022 | Abandon | 47 | 0 | 1 | Yes | No |
| 15959715 | METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTION | April 2018 | March 2022 | Abandon | 47 | 0 | 1 | No | No |
| 15959735 | METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTION | April 2018 | February 2022 | Abandon | 46 | 0 | 1 | No | No |
| 15959498 | RECOMBINANT BACTERIAL HOST CELL FOR PROTEIN EXPRESSION | April 2018 | October 2021 | Allow | 42 | 6 | 0 | Yes | No |
| 15945388 | Oligonucleotides and Methods for Detecting KRAS and PIK3CA Mutations | April 2018 | February 2021 | Allow | 34 | 0 | 2 | No | No |
| 15765420 | METHODS AND COMPOSITIONS FOR GENERATING CRISPR/CAS GUIDE RNAS | April 2018 | November 2021 | Allow | 43 | 0 | 1 | No | No |
| 15934945 | NUCLEOBASE EDITORS COMPRISING NUCLEIC ACID PROGRAMMABLE DNA BINDING PROTEINS | March 2018 | October 2021 | Allow | 43 | 2 | 1 | Yes | No |
| 15925544 | Methods and Compositions for RNA-Directed Target DNA Modification and for RNA-Directed Modulation of Transcription | March 2018 | June 2019 | Allow | 15 | 2 | 0 | Yes | No |
| 15920222 | METHODS AND COMPOSITIONS FOR DETECTING A TARGET RNA | March 2018 | September 2019 | Allow | 18 | 2 | 0 | Yes | No |
| 15915020 | METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTION | March 2018 | December 2020 | Abandon | 33 | 0 | 1 | No | No |
| 15897455 | METHOD OF EVALUATING CELLULITE AND METHOD OF EVALUATING CELLULITE-EFFECTIVE DRUG USING FIBULIN-3 AND/OR SARCOGLYCAN GAMMA AS AN INDICATOR | February 2018 | April 2020 | Allow | 26 | 0 | 0 | Yes | No |
| 15897089 | TYPE V CRISPR/CAS EFFECTOR PROTEINS FOR CLEAVING SSDNAS AND DETECTING TARGET DNAS | February 2018 | December 2018 | Allow | 10 | 1 | 1 | No | No |
| 15751426 | IMPROVEMENTS IN OR RELATING TO DNA RECOMBINATION | February 2018 | October 2020 | Allow | 33 | 3 | 1 | Yes | No |
| 15890561 | DNA Editing Using Relatively Long Single-Stranded DNA and CRISPR/Cas9 to Increase Success Rate in Methods for Preparing Transgenic Embryos and Animals | February 2018 | September 2022 | Allow | 55 | 6 | 0 | Yes | Yes |
| 15884329 | METHOD FOR PREPARING RECOMBINANT ADENO-ASSOCIATED VIRUS | January 2018 | September 2020 | Allow | 31 | 2 | 0 | No | No |
| 15883955 | IMAGING INDIVIDUAL MRNA MOLECULES USING MULTIPLE SINGLY LABELED PROBES | January 2018 | May 2021 | Abandon | 40 | 2 | 0 | Yes | No |
| 15863005 | COMPOSITIONS AND METHODS IDENTIFYING AND USING STEM CELL DIFFERENTIATION MARKERS | January 2018 | December 2021 | Abandon | 47 | 2 | 1 | Yes | No |
| 15839817 | GENOME EDITING DETECTION | December 2017 | August 2022 | Abandon | 56 | 4 | 1 | Yes | No |
| 15839820 | GENOME EDITING ENHANCEMENT | December 2017 | November 2021 | Allow | 47 | 3 | 1 | Yes | No |
| 15735941 | NEW CRISPR ASSAYS | December 2017 | July 2020 | Abandon | 31 | 0 | 1 | Yes | No |
| 15829445 | METHODS, COMPOSITIONS, AND KITS FOR NUCLEIC ACID ANALYSIS | December 2017 | July 2020 | Abandon | 31 | 2 | 1 | No | No |
| 15821456 | METHODS OF PREDICTING OSTEOARTHRITIS | November 2017 | July 2021 | Abandon | 44 | 2 | 1 | No | No |
| 15574748 | REPORTER CAS9 VARIANTS AND METHODS OF USE THEREOF | November 2017 | September 2022 | Abandon | 58 | 2 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner HAMMELL, NEIL P.
With a 44.4% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 17.8% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner HAMMELL, NEIL P works in Art Unit 1636 and has examined 417 patent applications in our dataset. With an allowance rate of 39.3%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 35 months.
Examiner HAMMELL, NEIL P's allowance rate of 39.3% places them in the 8% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by HAMMELL, NEIL P receive 2.44 office actions before reaching final disposition. This places the examiner in the 67% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by HAMMELL, NEIL P is 35 months. This places the examiner in the 38% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +40.3% benefit to allowance rate for applications examined by HAMMELL, NEIL P. This interview benefit is in the 86% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 9.5% of applications are subsequently allowed. This success rate is in the 6% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 18.4% of cases where such amendments are filed. This entry rate is in the 23% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.
When applicants request a pre-appeal conference (PAC) with this examiner, 111.1% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 80% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.
This examiner withdraws rejections or reopens prosecution in 62.5% of appeals filed. This is in the 40% percentile among all examiners. Of these withdrawals, 73.3% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows below-average willingness to reconsider rejections during appeals. Be prepared to fully prosecute appeals if filed.
When applicants file petitions regarding this examiner's actions, 42.2% are granted (fully or in part). This grant rate is in the 32% percentile among all examiners. Strategic Note: Petitions show below-average success regarding this examiner's actions. Ensure you have a strong procedural basis before filing.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 1% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 2.4% of allowed cases (in the 73% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.